Interventional Oncology Market

Interventional Oncology Market by Product (Radiofrequency, microwave, cryoablation, embolization, guidewires), Procedures (Thermal Ablation, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis) - Global Forecast to 2024

Report Code: MD 6975 Mar, 2019, by marketsandmarkets.com

[180 Pages Report] The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024. The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research.

Interventional Oncology Market

By product, the ablation devices segment is expected to grow at the highest rate during the forecast period

Based on product, the interventional oncology market is segmented into ablation devices, embolization devices, and support devices. The embolization devices segment accounted for the largest share of the interventional oncology market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer, product enhancements, and the increasing adoption of Yttrium-90 radioembolic agents in emerging countries.

By procedure, the transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT) segment was the largest contributor to the interventional oncology market in 2018

Based on procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. In 2018, the TARE/SIRT procedures segment accounted for the largest market share majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents (which are used in these procedures).

The liver cancer segment was the largest contributor to the interventional oncology market, by cancer type, in 2018

Based on cancer type, the interventional oncology market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers (includes pediatric cancer, prostate cancer, and breast cancer). The liver cancer segment accounted for the largest share of the interventional oncology market in 2018. The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities for developing advanced liver cancer therapies using interventional oncology.

Asia Pacific is expected to grow at the highest CAGR during the forecast period

The Asia Pacific regional market is expected to grow at the highest CAGR during the forecast period. Emerging economies in the region such as India, China, and South Korea, along with developed markets such as Japan and Australia, are offering high-growth opportunities for market players in the field of interventional oncology. This can be attributed to factors such as the increasing adoption of interventional oncology procedures, growing incidence of cancer, and the growing geriatric population.

Interventional Oncology Market

Key Market Players

The major players operating in the interventional oncology market include BTG plc (UK), Medtronic (Ireland), Boston Scientific (US), Terumo (Japan), Merit Medical (US), Sirtex (China), AngioDynamics (US), Ethicon (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), and Trisalus Lifesciences (US), among others.

An analysis of the market developments between 2015 and 2019 revealed that several growth strategies such as product launches and enhancements, partnerships, agreements, and strategic acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the interventional oncology market. Among these business strategies, partnerships and agreements were the most widely adopted growth strategies by market players.

Medtronic (Ireland) dominated the global interventional oncology market. The company focuses on adopting various organic growth strategies like product launches & approvals and inorganic growth strategies, such as acquisitions and collaborations, to expand its presence and share in the interventional oncology market. In line with this, the company launched various tumor management products like the OptiSphere Embolization Spheres and OsteoCool RF Ablation Systems and received US FDA clearance in 2018 and 2017 for cancer palliation and treatment, which helped to expand its presence in the market.

Recent Developments:

  • In 2017, Terumo Corporation (Japan) launched the QuiremSpheres Microspheres in Europe.
  • In 2017, Medtronic PLC (Ireland) launched its OptiSphere embolization spheres designed for hypervascular tumor embolization in the US.
  • In 2016, Ethicon (Johnson and Johnson, US) acquired NeuWave Medical, Inc. (US), and consequently the NeuWave microwave ablation portfolio with the aim to expand its product portfolio in the interventional oncology market.

Key Questions Addressed by the Report:

  • What are the growth opportunities related to the adoption of interventional oncology across major regions in the future?
  • Emerging countries have immense opportunities for the growth and adoption of interventional oncology procedures. Will this scenario continue in the next five years?
  • Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?
  • What are the cancer types that are treated by interventional oncology procedures? Can these procedures replace surgery?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 20)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Stakeholders

2 Research Methodology (Page No. - 23)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
    2.2 Market Size Estimation
           2.2.1 Product-Based Market Estimation
           2.2.2 Primary Research Validation
    2.3 Market Breakdown and Data Triangulation
    2.4 Research Limitations and Assumptions
           2.4.1 Limitations
           2.4.2 Assumptions

3 Executive Summary (Page No. - 33)

4 Premium Insights (Page No. - 36)
    4.1 Interventional Oncology: Market Overview
    4.2 Geographic Analysis: Interventional Oncology Market, By Product
    4.3 Asia Pacific: Ablation Devices Market, By Type (2018)
    4.4 Europe: Interventional Oncology Market, By Cancer Type (2018)
    4.5 Interventional Oncology Market, By Procedure, 2019 vs 2024 (USD Million)
    4.6 Geographical Snapshot of the Interventional Oncology Market

5 Market Overview (Page No. - 42)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Rising Patient Preference for Minimally Invasive Procedures
                    5.2.1.2 Expansion of the Target Patient Population
                    5.2.1.3 Increasing Public-Private Funding and Government Support for Interventional Oncology
                    5.2.1.4 Technological Advancements in Interventional Oncology
           5.2.2 Restraints
                    5.2.2.1 Dearth of Well-Trained and Skilled Radiologists and Oncologists
                    5.2.2.2 Unfavorable Regulations
           5.2.3 Opportunities
                    5.2.3.1 Emerging Economies Offer High Growth Potential
                    5.2.3.2 Rising Awareness About the Benefits of Interventional Oncology
           5.2.4 Challenges
                    5.2.4.1 Limited Clinical Data to Support Therapeutic Efficacy
                    5.2.4.2 Strong Market Positioning of Alternative Therapies
    5.3 Market Trends
           5.3.1 Personalized Or Precision Interventional Oncology

6 Interventional Oncology Market, By Product (Page No. - 48)
    6.1 Introduction
    6.2 Embolization Devices
           6.2.1 Interventional Oncology Embolization Devices Market Split, By Procedure
           6.2.2 Interventional Oncology Embolization Devices Market Split, By Cancer Type
           6.2.3 Radioembolic Agents
                    6.2.3.1 Radioembolic Agents Dominated the Interventional Oncology Embolization Devices Market in 2018
                               6.2.3.1.1 Radioembolic Agents Market Split, By Procedure
                               6.2.3.1.2 Radioembolic Agents Market Split, By Cancer Type
           6.2.4 Non-Radioactive Embolic Agents
                    6.2.4.1 Embolization Procedures Cannot Be Used to Treat Cancers in Advanced Stages, Which is A Major Factor Restraining Market Growth
                               6.2.4.1.1 Non-Radioactive Embolic Agents Market Split, By Procedure
                               6.2.4.1.2 Non-Radioactive Embolic Agents Market Split, By Cancer Type
    6.3 Ablation Devices
           6.3.1 Technological Advancements in Ablation Devices—A Key Driver for Market Growth
                    6.3.1.1 Interventional Oncology Ablation Devices Market Split, By Procedure
                    6.3.1.2 Interventional Oncology Ablation Devices Market Split, By Cancer Type
           6.3.2 Radiofrequency (RF) Ablation Devices
                    6.3.2.1 Growing Competition Among Different Technologies Offered By Key Players, Backed By Long-Term Clinical Efficacy Data, to Drive the RF Ablation Devices Market
                               6.3.2.1.1 Radiofrequency Ablation Devices Market Split, By Procedure
                               6.3.2.1.2 Radiofrequency Ablation Devices Market Split, By Cancer Type
           6.3.3 Microwave Ablation Devices
                    6.3.3.1 Microwave Ablation Enables the Simultaneous Treatment of Multiple Lesions—A Key Factor Driving Market Growth
                               6.3.3.1.1 Microwave Ablation Devices Market Split, By Procedure
                               6.3.3.1.2 Microwave Ablation Devices Market Split, By Cancer Type
           6.3.4 Cryoablation Devices
                    6.3.4.1 Advantages of Cryoablation Over Other Thermal Ablation Techniques to Drive Market Growth in the Coming Years
                               6.3.4.1.1 Cryoablation Devices Market Split, By Procedure
                               6.3.4.1.2 Cryoablation Devices Market Split, By Cancer Type
           6.3.5 Other Ablation Devices
                    6.3.5.1 Other Ablation Devices Market Split, By Procedure
                    6.3.5.2 Other Ablation Devices Market Split, By Cancer Type
    6.4 Support Devices
           6.4.1 Interventional Oncology Support Devices Market Split, By Procedure
           6.4.2 Interventional Oncology Support Devices Market Split, By Cancer Type
           6.4.3 Microcatheters
                    6.4.3.1 Regulatory Approvals Driving the Growth of the Microcatheters Market
                               6.4.3.1.1 Microcatheters Market Split, By Procedure
                               6.4.3.1.2 Microcatheters Market Split, By Cancer Type
           6.4.4 Guidewires
                    6.4.4.1 Advancements in Guidewire Construction and the Launch of New and Advanced Products are the Major Factors Driving the Growth of This Market
                               6.4.4.1.1 Guidewires Market Split, By Procedure
                               6.4.4.1.2 Guidewires Market Split, By Cancer Type

7 Interventional Oncology Market, By Procedure (Page No. - 73)
    7.1 Introduction
    7.2 Thermal Tumor Ablation
           7.2.1 Increasing Clinical Evidence is A Major Factor Driving Market Growth
    7.3 Non-Thermal Tumor Ablation
           7.3.1 Nanoknife has Emerged as A Potential Alternative to Thermal Tumor Ablation Techniques
    7.4 Transcatheter Arterial Chemoembolization
           7.4.1 Ability to Treat Small and Large-Sized Tumors – A Major Factor Driving the Demand for Tace Procedures
    7.5 Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
           7.5.1 Tare Shows Greater Clinical Efficacy as Compared to Tace
    7.6 Transcatheter Arterial Embolization/Bland Embolization
           7.6.1 Increasing Clinical Evidence for Tare and Tace to Restrain Growth of This Market

8 Interventional Oncology Market, By Cancer Type (Page No. - 82)
    8.1 Introduction
           8.1.1 Liver Cancer
                    8.1.1.1 Increasing Disease Prevalence and Rising Research Activity are Driving Market Growth
           8.1.2 Lung Cancer
                    8.1.2.1 Increasing Number of Cancer Cases Will Drive the Demand for Interventional Oncology Procedures
           8.1.3 Bone Cancer
                    8.1.3.1 Interventional Oncology Procedures Can Eliminate Tumors Directly and Relieve Pain
           8.1.4 Kidney Cancer
                    8.1.4.1 Interventional Oncology Procedures are Appropriate for Patients With A Genetic Disposition for Multiple Tumors
           8.1.5 Other Cancers

9 Interventional Oncology Market, By Region (Page No. - 89)
    9.1 Introduction
    9.2 North America
           9.2.1 US
                    9.2.1.1 US to Dominate the North American Interventional Oncology Market
           9.2.2 Canada
                    9.2.2.1 Public-Private Initiatives to Support the Adoption of Interventional Oncology Procedures in Canada
    9.3 Europe
           9.3.1 Germany
                    9.3.1.1 Germany is the Fastest-Growing Market in Europe
           9.3.2 UK
                    9.3.2.1 Increasing Awareness and Support for Cancer-Related Activities to Drive Market Growth in the UK
           9.3.3 France
                    9.3.3.1 Radiofrequency Ablation Dominated the Ablation Devices Market in France
           9.3.4 Rest of Europe
    9.4 Asia Pacific
           9.4.1 Japan
                    9.4.1.1 Rising Geriatric Population and Universal Healthcare Reimbursement are the Major Driving Factors
           9.4.2 China
                    9.4.2.1 Increasing Cancer Incidence and Growing Patient Population to Drive Market Growth in China
           9.4.3 India
                    9.4.3.1 Improving Research Capabilities Coupled With the Expansion of Key Players to Drive Market Growth in India
           9.4.4 Rest of Asia Pacific
    9.5 Latin America
           9.5.1 Brazil
                    9.5.1.1 Brazil to Account for the Largest Share of the Latin American Interventional Oncology Market
           9.5.2 Mexico
                    9.5.2.1 Growing Awareness Campaigns and Rising Incidence of Cancer to Drive Market Growth in Mexico
           9.5.3 Rest of Latin America
    9.6 Middle East and Africa
           9.6.1 Improving Healthcare Infrastructure and Rising Incidence of Cancer are Driving Growth in the Middle East and Africa

10 Competitive Landscape (Page No. - 137)
     10.1 Overview
     10.2 Global Market Share Analysis, 2017
     10.3 Competitive Scenario (2015 - 2019)
             10.3.1 Key Product Launches
             10.3.2 Key Acquisitions
             10.3.3 Key Agreements and Collaborations
     10.4 Vendor Dive Overview
     10.5 Vendor Inclusion Criteria
     10.6 Vendor Dive
             10.6.1 Vanguards
             10.6.2 Innovators
             10.6.3 Dynamic Differentiators
             10.6.4 Emerging Companies

11 Company Profiles (Page No. - 142)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     11.1 Healthtronics, Inc.
     11.2 Trod Medical
     11.3 Sanarus Technologies, Inc.
     11.4 Teleflex, Inc.
     11.5 Imbiotechnologies Ltd.
     11.6 Medwaves, Inc.
     11.7 Icecure Medical
     11.8 Terumo Corporation
     11.9 Medtronic PLC
     11.10 BTG PLC
     11.11 Johnson & Johnson
     11.12 Merit Medical Systems, Inc.
     11.13 Boston Scientific Corporation
     11.14 Angiodynamics, Inc.
     11.15 Cook Medical

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 172)
     12.1 Discussion Guide
     12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.3 Available Customizations
     12.4 Related Reports
     12.5 Author Details


List of Tables (140 Tables)

Table 1 Interventional Oncology Market, By Product, 2017–2024 (USD Million)
Table 2 Recent Product Launches and Approvals of Embolization Devices
Table 3 Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 4 Interventional Oncology Embolization Devices Market, By Region, 2017–2024 (USD Million)
Table 5 Interventional Oncology Embolization Devices Market, By Procedure, 2017–2024 (USD Million)
Table 6 Interventional Oncology Embolization Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 7 Radioembolic Agents Offered By Major Market Players
Table 8 Radioembolic Agents Market, By Region, 2017–2024 (USD Million)
Table 9 Radioembolic Agents Market, By Procedure, 2017–2024 (USD Million)
Table 10 Radioembolic Agents Market, By Cancer Type, 2017–2024 (USD Million)
Table 11 Non-Radioactive Embolic Agents Offered By Major Market Players
Table 12 Non-Radioactive Embolic Agents Market, By Region, 2017–2024 (USD Million)
Table 13 Non-Radioactive Embolic Agents Market, By Procedure, 2017–2024 (USD Million)
Table 14 Non-Radioactive Embolic Agents Market, By Cancer Type, 2017–2024 (USD Million)
Table 15 Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 16 Interventional Oncology Ablation Devices Market, By Region, 2017–2024 (USD Million)
Table 17 Interventional Oncology Ablation Devices Market, By Procedure, 2017–2024 (USD Million)
Table 18 Interventional Oncology Ablation Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 19 Radiofrequency Ablation Devices Offered By Major Market Players
Table 20 Radiofrequency Ablation Devices Market, By Region, 2017–2024 (USD Million)
Table 21 Radiofrequency Ablation Devices Market, By Procedure, 2017–2024 (USD Million)
Table 22 Radiofrequency Ablation Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 23 Microwave Ablation Devices Market, By Region, 2017–2024 (USD Million)
Table 24 Microwave Ablation Devices Market, By Procedure, 2017–2024 (USD Million)
Table 25 Microwave Ablation Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 26 Cryoablation Devices Market, By Region, 2017–2024 (USD Million)
Table 27 Cryoablation Devices Market, By Procedure, 2017–2024 (USD Million)
Table 28 Cryoablation Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 29 Other Ablation Devices Market, By Region, 2017–2024 (USD Million)
Table 30 Other Ablation Devices Market, By Procedure, 2017–2024 (USD Million)
Table 31 Other Ablation Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 32 Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 33 Interventional Oncology Support Devices Market, By Region, 2017–2024 (USD Million)
Table 34 Interventional Oncology Support Devices Market, By Procedure, 2017–2024 (USD Million)
Table 35 Interventional Oncology Support Devices Market, By Cancer Type, 2017–2024 (USD Million)
Table 36 Microcatheters Market, By Region, 2017–2024 (USD Million)
Table 37 Microcatheters Market, By Procedure, 2017–2024 (USD Million)
Table 38 Microcatheters Market, By Cancer Type, 2017–2024 (USD Million)
Table 39 Guidewires Market, By Region, 2017–2024 (USD Million)
Table 40 Guidewires Market, By Procedure, 2017–2024 (USD Million)
Table 41 Guidewires Market, By Cancer Type, 2017–2024 (USD Million)
Table 42 Interventional Oncology Market, By Procedure, 2017–2024 (USD Million)
Table 43 Thermal Tumor Ablation Procedures Market, By Region, 2017–2024 (USD Million)
Table 44 Non-Thermal Tumor Ablation Procedures Market, By Region, 2017–2024 (USD Million)
Table 45 Transcatheter Arterial Chemoembolization Procedures Market, By Region, 2017–2024 (USD Million)
Table 46 Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy Procedures Market, By Region, 2017–2024 (USD Million)
Table 47 Transcatheter Arterial Embolization/Bland Embolization Procedures Market, By Region, 2017–2024 (USD Million)
Table 48 Interventional Oncology Market, By Cancer Type, 2017–2024 (USD Million)
Table 49 Market for Liver Cancer, By Region, 2017–2024 (USD Million)
Table 50 Market for Lung Cancer, By Region, 2017–2024 (USD Million)
Table 51 Market for Bone Cancer, By Region, 2017–2024 (USD Million)
Table 52 Market for Kidney Cancer, By Region, 2017–2024 (USD Million)
Table 53 Market for Other Cancers, By Region, 2017–2024 (USD Million)
Table 54 Market, By Region, 2017–2024 (USD Million)
Table 55 North America: Interventional Oncology Market, By Country, 2017–2024 (USD Million)
Table 56 North America: Market, By Product, 2017–2024 (USD Million)
Table 57 North America: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 58 North America: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 59 North America: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 60 North America: Market, By Procedure, 2017–2024 (USD Million)
Table 61 North America: Market, By Cancer Type, 2017–2024 (USD Million)
Table 62 US: Market, By Product, 2017–2024 (USD Million)
Table 63 US: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 64 US: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 65 US: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 66 Canada: Market, By Product, 2017–2024 (USD Million)
Table 67 Canada: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 68 Canada: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 69 Canada: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 70 Europe: Market, By Country, 2017–2024 (USD Million)
Table 71 Europe: Market, By Product, 2017–2024 (USD Million)
Table 72 Europe: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 73 Europe: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 74 Europe: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 75 Europe: Market, By Procedure, 2017–2024 (USD Million)
Table 76 Europe: Market, By Cancer Type, 2017–2024 (USD Million)
Table 77 Germany: Market, By Product, 2017–2024 (USD Million)
Table 78 Germany: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 79 Germany: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 80 Germany: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 81 UK: Market, By Product, 2017–2024 (USD Million)
Table 82 UK: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 83 UK: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 84 UK: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 85 France: Market, By Product, 2017–2024 (USD Million)
Table 86 France: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 87 France: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 88 France: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 89 RoE: Market, By Product, 2017–2024 (USD Million)
Table 90 RoE: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 91 RoE: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 92 RoE: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 93 Asia Pacific: Market, By Country, 2017–2024 (USD Million)
Table 94 Asia Pacific: Market, By Product, 2017–2024 (USD Million)
Table 95 Asia Pacific: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 96 Asia Pacific: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 97 Asia Pacific: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 98 Asia Pacific: Market, By Procedure, 2017–2024 (USD Million)
Table 99 Asia Pacific: Market, By Cancer Type, 2017–2024 (USD Million)
Table 100 Japan: Market, By Product, 2017–2024 (USD Million)
Table 101 Japan: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 102 Japan: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 103 Japan: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 104 China: Market, By Product, 2017–2024 (USD Million)
Table 105 China: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 106 China: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 107 China: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 108 India: Market, By Product, 2017–2024 (USD Million)
Table 109 India: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 110 India: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 111 India: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 112 RoAPAC: Market, By Product, 2017–2024 (USD Million)
Table 113 RoAPAC: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 114 RoAPAC: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 115 RoAPAC: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 116 Latam: Market, By Country, 2017–2024 (USD Million)
Table 117 Latam: Market, By Product, 2017–2024 (USD Million)
Table 118 Latam: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 119 Latam: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 120 Latam: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 121 Latam: Market, By Procedure, 2017–2024 (USD Million)
Table 122 Latam: Market, By Cancer Type, 2017–2024 (USD Million)
Table 123 Brazil: Market, By Product, 2017–2024 (USD Million)
Table 124 Brazil: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 125 Brazil: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 126 Brazil: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 127 Mexico: Market, By Product, 2017–2024 (USD Million)
Table 128 Mexico: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 129 Mexico: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 130 Mexico: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 131 RoLA: Market, By Product, 2017–2024 (USD Million)
Table 132 RoLA: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 133 RoLA: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 134 RoLA: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 135 MEA: Market, By Product, 2017–2024 (USD Million)
Table 136 MEA: Interventional Oncology Ablation Devices Market, By Type, 2017–2024 (USD Million)
Table 137 MEA: Interventional Oncology Embolization Devices Market, By Type, 2017–2024 (USD Million)
Table 138 MEA: Interventional Oncology Support Devices Market, By Type, 2017–2024 (USD Million)
Table 139 MEA: Market, By Procedure, 2017–2024 (USD Million)
Table 140 MEA: Interventional Oncology Market, By Cancer Type, 2017–2024 (USD Million)


List of Figures (33 Figures)

Figure 1 Interventional Oncology Market: Research Methodology Steps
Figure 2 Research Design
Figure 3 Breakdown of Primaries: Global Interventional Oncology Market
Figure 4 Research Methodology: Hypothesis Building
Figure 5 Bottom-Up Approach Market Size Estimation: Interventional Oncology Market
Figure 6 Top-Down Approach Market Size Estimation: Interventional Oncology Market
Figure 7 Data Triangulation Methodology
Figure 8 Interventional Oncology Market Share, By Product, 2018
Figure 9 Interventional Oncology Market Share, By Procedure, 2018
Figure 10 Interventional Oncology Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 11 Geographical Snapshot of the Interventional Oncology Market
Figure 12 Rising Preference for Minimally Invasive Procedures is Driving the Growth of the Interventional Oncology Market
Figure 13 Ablation Devices Segment to Witness High Growth in the Market During the Forecast Period
Figure 14 Radiofrequency Ablation Segment Accounted for the Largest Share of the Asia Pacific Ablation Devices Market in 2018
Figure 15 Liver Cancer Segment Commanded the Largest Share of the European Interventional Oncology Market in 2018
Figure 16 Thermal Tumor Ablation Segment to Witness the Highest Growth in the Forecast Period
Figure 17 Asia Pacific to Register the Highest CAGR in the Interventional Oncology Market During the Forecast Period
Figure 18 Interventional Oncology Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Liver Cancer Segment to Dominate the Interventional Oncology Market, By Cancer Type, During the Forecast Period
Figure 20 Interventional Oncology Market: Geographic Snapshot
Figure 21 North America: Interventional Oncology Market Snapshot
Figure 22 Asia Pacific: Interventional Oncology Market Snapshot
Figure 23 Key Developments in the Interventional Oncology Market From 2015 to 2019
Figure 24 Medtronic Held the Leading Position in the Interventional Oncology Market in 2017
Figure 25 Vendor Dive: Evaluation Overview
Figure 26 Teleflex: Company Snapshot
Figure 27 Terumo Corporation: Company Snapshot
Figure 28 Medtronic: Company Snapshot
Figure 29 BTG PLC: Company Snapshot
Figure 30 Johnson & Johnson: Company Snapshot
Figure 31 Merit Medical: Company Snapshot
Figure 32 Boston Scientific Corporation: Company Snapshot
Figure 33 Angiodynamics: Company Snapshot

The study involved four major activities to estimate the current size of the interventional oncology market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.

Secondary Research

This research study involved the extensive use of secondary sources, directories, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva), along with government databases, which were used to identify and collect information for this method-based, market-oriented, and commercial study of the interventional oncology market.

In-depth interviews were conducted with various primary respondents that mainly include key industry participants, medical practitioners, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and verify critical qualitative and quantitative information as well as to assess prospects of the interventional oncology market.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the interventional oncology market scenario through secondary research. A significant number of primary interviews were conducted with both the demand (healthcare providers, research institutes, physicians, and healthcare professionals) and supply sides (developers, manufacturers, and distributors of interventional oncology products). The primaries interviewed for this study include experts from the interventional oncology and minimally invasive devices industry (such as CEOs, VPs, directors, sales heads, and marketing managers of tier 1, 2, and 3 companies engaged in offering interventional oncology solutions across the globe) and administrators & purchase managers of hospitals, interventional radiologists, interventional oncologists, ambulatory care centers, and healthcare service providers.

Around 60% and 40% primary interviews were conducted with the supply and demand sides, respectively. A robust primary research methodology has been adopted to validate the contents of the report and to fill gaps. Telephonic and e-mail communications were adopted to conduct interviews (questionnaires were designed and sent to primary participants as per their convenience). The following is the breakdown of primary respondents:

Interventional Oncology Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

A detailed market estimation approach was followed to estimate and validate the size of the interventional oncology market and other dependent submarkets, as mentioned above. The key players in the interventional oncology market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. Research methodology includes the study of the annual and quarterly financial reports of the top market players as well as interviews with industry experts for key insights (both quantitative and qualitative trends) on the interventional oncology market. All percentage shares, splits, and breakdowns were determined by using secondary sources and verified through primary sources. All the possible parameters that affect the market segments covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. This data was consolidated and added to detailed inputs and analysis from MarketsandMarkets, and presented in this report. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size of the interventional oncology industry from the market estimation approach explained above, the global market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact market value data, data triangulation and market breakdown methodology methods were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand- and supply-side analysis.

Report Objectives

  • To define, describe, and forecast the global interventional oncology market on the basis of product, procedure, cancer type, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the total interventional oncology market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of the market segments with respect to four main regions, namely, North America (US and Canada), Europe (Germany, France, the UK, and the Rest of Europe), Asia Pacific (China, Japan, India, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America), and the Middle East & Africa (MEA).
  • To strategically profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; business expansions and research & development activities in the interventional oncology market

Scope of the Report

Report Metric

Details

Market Size Available for Years

2017–2024

Base Year Considered

2017

Forecast Period

2018–2024

Forecast Units

Value (USD)

Segments Covered

Products, Procedure, Cancer Type, and Region

Geographies Covered

North America (US & Canada), Europe (Germany, France, UK, and RoE), APAC (Japan, China, India, and RoAPAC), and LATAM (Brazil, Mexico, and RoLA) and MEA.

Companies Covered

The major players in the market include Medtronic (Ireland), Boston Scientific (US), BTG plc (UK), Merit Medical Systems (US), and Terumo (Japan). The other prominent players operating in the overall interventional oncology market include AngioDynamics (US), Ethicon (part of J&J) (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), and Interface Biomaterials BV (Netherlands), among others.

This research report categorizes the interventional oncology market based on product, procedure, cancer type, and region.

Interventional Oncology Market, by Product

  • Embolization Devices
    • Radioembolic Agents
    • Non-radioactive Embolic Agents
  • Ablation Devices
    • Radiofrequency Ablation Devices
    • Microwave Ablation Devices
    • Cryoablation Devices
    • Other Ablation Devices
  • Support Devices
    • Microcatheters
    • Guidewires

Interventional Oncology Market, by Procedure

  • Thermal Tumor Ablation
  • Non-thermal Tumor Ablation
  • Transcatheter Arterial Chemoembolization (TACE)
  • Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT)
  • Transcatheter Arterial Embolization (TAE) or Bland Embolization

Interventional oncology Market, by Cancer Type

  • Liver Cancer
  • Kidney Cancer
  • Lung Cancer
  • Bone Cancer
  • Other Cancers

Interventional oncology Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • RoLA
  • Middle East & Africa

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global interventional oncology market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Report Code
MD 6975
Published ON
Mar, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Interventional Oncology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home